Peerview Family Medicine & General Practice Cme/cne/cpe Audio Podcast

Go online to PeerView.com/NXB860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Growing appreciation of the importance of B-cell–targeted therapies in multiple sclerosis (MS) management has spurred research into the potential role that Bruton tyrosine kinase (BTK) inhibitors may play in MS management. In this activity, based on a recent live satellite symposium, expert faculty will put BTK inhibitors into context, starting with the expanding understanding of the inflammatory and neurodegenerative processes of MS, the roles of B cells, microglia, and T cells, and how the ongoing investigations of BTK inhibitors as possible MS treatments build upon the successes of B-cell–targeted therapies. They will also review the evidence related to current clinical trials and engage learners in a case-based discussion exploring how BTK inhibitors might someday be deployed to address unmet needs of individuals with MS. Upon completion of this CE activity, participants wil

Go online to PeerView.com/KHE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an allergy expert discusses the mechanism of action and current treatment approaches for managing IgE-mediated food allergies. Upon completion of this accredited CE activity, participants should be better able to: Discuss key limitations associated with current treatment approaches for managing food allergies, Differentiate the mechanisms of action of current and emerging treatments for IgE-mediated food allergies, Identify patients with IgE-mediated food allergies who would likely derive benefit from treatment with IgE-blocking therapies.

Go online to PeerView.com/WBN860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Obesity is a complex chronic disease that can cause serious health complications. Current guidelines advocate for the use of multiple interventions to address the genetic, behavioral, and metabolic factors that contribute to insufficient weight loss or weight regain. Weight-loss pharmacotherapy is a recommended approach with distinct mechanisms of action that can affect different aspects of obesity pathophysiology. In this activity, based on a recent live web broadcast, leading experts examine the pathophysiology of obesity, focusing on metabolic adaptation and the role of GLP-1 in energy consumption and expenditure and review the latest evidence for GLP-1–based agents. The panel also discusses clinically relevant patient scenarios to offer practical guidance on identifying ideal candidates for weight-loss medications and integrating these medications into individualized treatme

Go online to PeerView.com/FFX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in Sjögren’s Syndrome reviews current concepts in the pathophysiology of pSS, and discusses the obstacles faced in recent clinical trials and how new approaches may overcome these obstacles in the future. Upon completion of this activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with primary Sjögren’s Syndrome, Describe key pathways involved in the pathology of primary Sjögren’s Syndrome and implications for treatment, Evaluate recent clinical trial data related to emerging treatment options for primary Sjögren’s Syndrome, Identify patients who might derive benefit from novel therapeutic options for primary Sjögren’s Syndrome.

Go online to PeerView.com/AZM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. This PeerView Clinical Consults activity features cardio-oncologist Javid Moslehi, MD, and medical oncologist Douglas B. Johnson, MD, MSCI, who explain why greater awareness is needed among cardiology professionals about the cardiac toxicities associated with cancer immunotherapies, known as immune-related adverse events (irAEs), and their clinical manifestations. These experts provide practical guidance on strategies and techniques for diagnosing, staging, and managing patients who present with various cardiac irAEs. This virtual session will engage participants with opportunities to participate in consultative assessments of real-world patient cases, including contributing to key aspects of diagnostic decision-making and deliberation of optimal strategies for collaborative mitigation of cardiac irAEs. Upon completion of this activity, participants should be better able to: Sum

Go online to PeerView.com/HNA860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in infectious diseases discuss employing PrEP and HIV prevention strategies across all age groups. Upon completion of this activity, participants should be better able to: Describe the biologic principles and HIV prevention benefit of PrEP, Discuss clinical data to support PrEP use in different age groups (eg, youth, adults, and older adults), Develop strategies for the healthcare team to employ culturally competent educational and counseling strategies to improve the uptake of prevention measures among patients at increased risk for HIV infection across the lifespan, Facilitate access to PrEP among youth, adults, and individuals aged 50 and older.

Go online to PeerView.com/CMG860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Intravitreal treatments have advanced rapidly to become the mainstay of therapy for DR/DME. Anti-VEGF agents and corticosteroid implants have demonstrated efficacy for reducing vision loss from DR/DME and may be administered adjunctively to laser photocoagulation. Increasingly, studies comparing these treatments in combination, in sequence, or in head-to-head trials are becoming available, helping to refine decisions regarding the right therapy for the right patient at the right time. Additionally, new intravitreal treatments offer the potential of even higher efficacy, greater safety, or longer intervals between retreatments. Join our panel of noted retina specialists for an engaging discussion of emerging agents, including a review of recent reported clinical trials and their implications for advancing patient-centered care for DR/DME. The expert dialogue will be complemented

Go online to PeerView.com/AZH860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in eosinophilic esophagitis discusses the latest research, data, and guidelines on novel and emerging targeted therapies. Upon completion of this CE activity, participants will be able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of eosinophilic esophagitis (EoE), Employ the latest clinical data, including evidence concerning novel and emerging targeted therapies, into treatment plans for the management of patients with EoE as they become available.

Go online to PeerView.com/FUM860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live symposium, experts in neurology explore the mechanisms of action of S1PR modulators approved for the treatment of multiple sclerosis (MS), highlighting the similarities and differences among treatment options and reviewing the efficacy and safety data for these therapies and their potential effects on markers of treatment response or disease progression (eg, brain atrophy, neurofilament protein levels, cognitive test results). The burden, assessment, and management of cognitive impairment in MS, which occurs in over 50% of people with MS and can greatly affect patients’ functioning and quality of life, is also examined in this activity. The expert faculty also present and discuss patient case scenarios, through which they explore best practices in the care of patients with varied disease presentations and clinical contexts. Upon completio

Go online to PeerView.com/CJC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this animated activity, an expert in dermatology discusses new and novel therapies addressing unmet patient needs in the management of chronic spontaneous urticaria (CSU). Upon completion of this CE activity, participants will be able to: Recognize CSU as a heterogeneous, disabling, and persistent disease with multiple comorbidities and consequences, Conduct a thorough medical history to guide the selection of adequate and relevant tests for the diagnostic workup in CSU, Discuss how recent insights into the pathogenesis of CSU have led to the development of novel therapeutic targets, Evaluate recent clinical trial data related to novel treatment options for CSU, Treat CSU in accordance with current evidence and expert recommendations, identifying patients who would likely derive benefit from newer therapeutic options.

Go online to PeerView.com/AXE860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses best practices to achieve treatment goals and improve quality of life for patients with prurigo nodularis and a patient provides a firsthand account concerning the great impact the disease can have. Upon completion of this CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with prurigo nodularis (PN), Discuss advances in the underlying pathophysiology of PN that have led to the identification of new therapeutic targets, Describe the clinical profiles of emerging treatment options for PN, Develop treatment plans for PN that are tailored to the individual needs of each patient, considering clinical presentation, comorbidities, and response to prior therapies.

Go online to PeerView.com/AEC860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. Despite the widespread use of surgery as a standard of care for tenosynovial giant cell tumor (TGCT), several therapeutic challenges remain, particularly in the setting of diffuse TGCT, where recurrent and difficult-to-treat disease can be present. In this activity, an orthopedic surgeon and medical oncologist debate the case-based management of challenging TGCT presentations, and illustrate the nuances of multidisciplinary collaboration when managing patients with TGCT. Throughout, the panelists profile a modern management synthesis that combines surgery, physical therapy, and the use of targeted agents, including for patients for whom surgery alone is unlikely to be beneficial. Upon completion of this CE activity, participants will be able to: Interpret the clinical signs and symptoms of localized and diffuse tenosynovial giant cell tumor (TGCT), including recurrent disease, U

Go online to PeerView.com/RSD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert dermatologist discusses the latest evidence from the 30th European Academy of Dermatology and Venereology Congress for current and emerging targeted biologic therapies for moderate to severe atopic dermatitis in adults and children. Upon completion of this accredited CE activity, participants should be better able to: Interpret recent developments in clinical research and treatment guidelines regarding the management of pediatric and adult patients with moderate to severe atopic dermatitis, Apply the latest clinical evidence on approved and emerging biologic therapies into personalized treatment plans for pediatric and adult patients with moderate to severe atopic dermatitis.

Go online to PeerView.com/JTZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in rheumatology discusses the recognition and management of axial spondyloarthritis (axSpA). Upon completion of this accredited CE activity, participants should be better able to: Describe axial spondyloarthritis (axSpA) pathophysiology and epidemiology and complications associated with diagnostic and treatment delays, Identify axSpA in patients with inflammatory back pain via assessment of medical history, musculoskeletal symptoms and findings, and extra-articular manifestations and comorbidities, Assess efficacy and safety data related to novel treatment options for axSpA, recognizing the potential clinical impact on the management of patients who do not respond well to traditional pharmacologic therapies, Employ treatment plans for individual patients with axSpA in accordance with current evidence, expert recommendations, and patient needs and pref

Go online to PeerView.com/NRZ860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, a hematology expert discusses the diagnostic assessment and management of von Willebrand disease, as well as available treatment options and strategies for shared decision-making. Upon completion of this accredited CE activity, participants should be better able to: Review the clinical presentation, phenotypic classification, and diagnostic workup of von Willebrand disease (VWD), Assess the latest evidence for available VWD treatments, including recombinant VW factor and other novel strategies, Engage patients and caregivers in shared decision-making to personalize VWD treatment, promote adherence, and minimize complications associated with poor adherence.

Go online to PeerView.com/BQR860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, based on a recent live satellite symposium held at HFSA 2021, expert faculty review the evidence for current and emerging treatment strategies for hypertrophic cardiomyopathy (HCM) using patient cases to illustrate the ways in which clinicians can adapt current practices and utilize shared decision-making to offer appropriate treatment options to patients with HCM. Upon completion of this activity, participants should be better able to: Recognize HCM’s pathophysiology and the associated disease burdens that may be experienced by patients (eg, health impact, quality of life, daily activities), Apply the latest recommendations and guidance for diagnosing, evaluating, and monitoring patients with HCM in a team-based manner, Evaluate current and emerging strategies for managing HCM in terms of efficacy, safety, and effects on burden of disease, Collaborate with pat

Go online to PeerView.com/ZZW860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in myelofibrosis discuss risk stratification, individualized care, and treatment strategies, including the use of JAK inhibitors and JAK inhibitor–based combinations. Upon completion of this accredited CE activity, participants should be better able to: Review modern risk stratification models, molecular features, cytogenetics, and clinical presentation of myelofibrosis, Evaluate the latest safety, efficacy, and tolerability data supporting the use of JAK inhibitors and other novel strategies, including JAK inhibitor–based combinations or sequencing approaches for managing transplant-eligible and transplant-ineligible patients with myelofibrosis, Address practical aspects of individualized care and risk-adapted therapy in myelofibrosis for managing lower- and higher-risk patients, including those failing prior JAK inhibitor therapy, Educate patients on

Go online to PeerView.com/GEX860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. An expert discusses the latest data on targeted treatments for biliary cancers and integrating precision medicine with new and emerging strategies. Upon completion of this accredited CE activity, participants should be better able to: Describe the biologic rationale for the use of targeted options in the management of advanced biliary cancers, such as those targeting FGFR genomic aberrations, multikinase tumor pathways, HER2 expression, NTRK gene fusions, IDH1/2 mutations, and immune checkpoint pathways, Appraise recent efficacy and safety data on newly available, guideline-based, and emerging therapeutic strategies for patients with advanced biliary cancers, including FGFR, IDH, TRK, multikinase, HER2, and immune checkpoint inhibitors, Summarize ongoing/accruing clinical trials investigating novel approaches, such as chemotherapy platforms, targeted agents, and immunotherapy, f

Go online to PeerView.com/FXS860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, an expert in dermatology discusses new and emerging therapies for patients with moderate to severe atopic dermatitis. Upon completion of this accredited CE activity, participants should be better able to: Describe key cytokine signaling pathways involved in the pathogenesis of atopic dermatitis (AD) and implications for treatment, Evaluate recent clinical trial data related to the efficacy and safety of new and emerging treatment options (eg, JAK inhibitors) for moderate to severe AD, Treat AD in accordance with current evidence and guidelines, identifying patients with moderate to severe disease who would likely derive benefit from novel therapeutic options, Discuss evidence and recommendations on the immunization and monitoring of patients with AD who are candidates for, or receiving, biological or small-molecule targeted immunomodulatory therapies.

Go online to PeerView.com/TWD860 to view the activity, download slides and practice aids, and complete the post-test to earn credit. In this activity, experts in psoriatic disease offer learners an in-depth look at the complex pathophysiology of psoriasis, current management paradigms, and challenges in the care of patients with moderate to severe disease. Upon completion of this accredited CE activity, participants should be better able to: Recognize the burden of disease and unmet needs experienced by patients with moderate to severe psoriasis, Discuss the rationale for blocking the JAK-STAT pathway with small molecules as a treatment approach to psoriasis, Compare and contrast novel JAK inhibitors for the treatment of psoriasis in the context of selectivity, efficacy, and safety, Treat psoriasis in accordance with current evidence and guidelines, identifying patients with moderate to severe disease, who would likely derive benefit from novel nonbiologic oral therapeutic options.